Welcome to our dedicated page for Hoth Therapeutics SEC filings (Ticker: HOTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Deciphering a biotech 10-K packed with clinical data, cash-runway tables, and licensing clauses is hard enough; doing it for Hoth Therapeutics—a company juggling BioLexa dermatology trials, HT-ALZ Alzheimer’s research, and HT-KIT oncology studies—can feel overwhelming. If you have ever asked, “How do I find Hoth Therapeutics’ 10-K risk factors?” or “Where are Hoth Therapeutics insider trading Form 4 transactions listed?”, you know the challenge.
Stock Titan solves it by pairing real-time EDGAR feeds with AI-powered summaries that explain filing language in plain English. Need the latest Hoth Therapeutics quarterly earnings report 10-Q filing or want Hoth Therapeutics Form 4 insider transactions real-time? Our platform alerts you the moment they post, then highlights trial expenses, grant income, and executive stock moves. Curious about a sudden 8-K? You will see Hoth Therapeutics 8-K material events explained—from FDA feedback to new collaboration deals—without digging through exhibits.
Every document type is covered: the Hoth Therapeutics annual report 10-K simplified shows R&D spend versus cash on hand; the proxy statement breaks down Hoth Therapeutics executive compensation so you can evaluate alignment; Form 4 pages track Hoth Therapeutics executive stock transactions Form 4 ahead of milestone readouts. Investors routinely use these insights to monitor insider confidence before Phase I data, compare quarter-over-quarter R&D costs, and gauge dilution risk. Whether you’re understanding Hoth Therapeutics SEC documents with AI for the first time or need a quick Hoth Therapeutics earnings report filing analysis, Stock Titan turns hundreds of pages into actionable clarity—so you spend time on decisions, not document hunts.
Hoth Therapeutics, Inc. reported $9.0 million in cash and cash equivalents at June 30, 2025, up from $7.0 million at year-end 2024, and total assets of $10.1 million. The company recorded a six-month net loss of $5.68 million versus $3.86 million in the prior-year period, driven in part by a $1.25 million immediate expensing of acquired patent applications and higher research and development spending. Weighted average shares increased materially, lowering six-month loss per share to $0.44 from $0.68 a year earlier despite a larger absolute loss.
Operating cash used was $5.16 million for the six months, while financing activities provided $7.13 million, including $5.625 million from warrant exercises. Management states current cash is sufficient to fund operations for at least 12 months from issuance, but additional capital will be required for longer-term development and regulatory plans. The company continues clinical and preclinical programs across multiple candidates and maintains an ATM facility with selling capacity expanded to $7.7 million.
Hoth Therapeutics has filed an 8-K report announcing the preparation of new presentation materials that management plans to use for company presentations starting June 24, 2025. The materials are included as Exhibit 99.1 to the Current Report.
Key points from the filing:
- The presentation materials contain summary information that should be considered alongside the company's SEC filings and other public announcements
- The company maintains discretion to update the materials but has no obligation to do so
- Information provided under Item 7.01 and Exhibit 99.1 is furnished rather than "filed" under SEC regulations
- The information will not be incorporated by reference into any Securities Act or Exchange Act filings
The filing was signed by CEO Robb Knie and includes the standard Cover Page Interactive Data File in Inline XBRL format.
Hoth Therapeutics, Inc. ("HOTH") reported that, on June 18, 2025, The Nasdaq Stock Market notified the company that its common stock satisfied the minimum bid price requirement of $1.00 per share for at least ten consecutive business days, thereby restoring full compliance with Nasdaq Listing Rule 5550(a)(2). The company disclosed the notification in this Form 8-K and simultaneously issued a press release, furnished as Exhibit 99.1.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
